key: cord-0771962-8lgkeeqq authors: Pindiprolu, Sai Kiran S.S.; Kumar, Chirravuri S Phani; Kumar Golla, Venu Sampath; Pindiproli, Likitha; Ramachandra, R.K. title: Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent date: 2020-05-30 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.109858 sha: df11423d4426b254dc353c855eb8a83a8a76d6f6 doc_id: 771962 cord_uid: 8lgkeeqq Coronavirus disease outbreak caused a severe public health burden all over the world. Salinomycin (SAL) is a broad-spectrum antibiotic that had drawn attention in selective targeting of cancer and viral infections. Recent drug screen identified SAL as a potent antiviral agent against SARS-CoV-2. In this review we discuss the potential of pulmonary delivery of SAL using nanostructured lipid carriers (NLCs) against SARS-CoV-2. Coronaviruses (CoVs) are enveloped, single-stranded RNA viruses belonging to the family Coronaviridae within the order Nidovirales. Coronaviruses (CoV) are of four different genera, α, β, γ, and δ CoVs. Among these β CoVs like SARS-CoV, Middle East respiratory syndrome (MERS-CoV), and novel coronavirus (SARS-CoV-2) is responsible for severe and potentially fatal respiratory infections. [1] [2] [3] It was reported that CoVs enter host cells Angiotensin-Converting Enzyme-2 (ACE-2) receptor-mediated endocytosis, which is a pH-dependent process. In this process, Spike (S) protein plays a major role in receptor binding and membrane fusion of SARS-CoV-2 for entry into host cells. It contains a large ectodomain, transmembrane anchor, and a short intracellular tail. The ectodomain of SARS-CoV-2 consists of two subunits. S1 subunit of SARS-CoV-2 is responsible for binding with the ACE-2 receptor for viral entry to host cells. Following receptor binding, the SARS-CoV-2 enter the cytosol of the host cell, by pH-dependent proteolytic cleavage of spike protein by TMPRSS2. Then the fusion of viral and host cell membranes occurs in acidified endosomes, allowing viral genomes to affect host cells with the aid of the S2 subunit [1, 4, 5] . Coronavirus disease 19 (COVID-19) caused by SARS-CoV-2 was the pandemic, affected nearly 1400000 people worldwide as on 7 April 2020, according to WHO. However, rapid spread, potential mortality, and lack of clinically approved drugs and vaccines against COVID-19 are the major challenges. There is a need, therefore, for quick discovery of drugs against this emerging infectious disease. However, the slow phase of discovery and associated costs are the major challenges in discovering drugs against SARS-CoV-2. Drug repurposing using existing drugs is an attractive strategy to accelerate drug discovery against COVID-19. Recently researchers focused on screening of FDA approved drugs against SARS-CoV-2 [6] [7] [8] . Salinomycin (SAL) is a carboxylic polyether ionophore isolated from Streptomyces albus. Ionophores show a broad spectrum of bioactivity, like antibacterial, antifungal, antiparasitic, antiviral, and recently, they are also used as anti-tumor agents [9] . However, poor absorption, low bioavailability, and off-target effects are the potential limitations for effective repurposing of SAL as an antiviral agent against SARS-CoV-2. In the present study, we, therefore, propose the pulmonary delivery of SAL using nanostructured lipid carriers (NLCs). In the present study, we proposed to prepare NLCs for intra-pulmonary delivery of SAL to prevent SARS-CoV-2 infection (Fig. 1) . The proposed drug delivery system with the following advantages:  Noninvasive means of administration  Localized delivery to lung epithelium directly  Avoid first-pass metabolism  Reduced off-target effects  Rapid and effective drug absorption For all enveloped viruses, the significant step of entry into host cell is fusion. SARS-CoV-2 fusion occurs in low pH with a half-maximal rate of fusion at pH 5.5. A compelling body of evidence suggests, SAL inhibits replication of viral RNA in the cytoplasm by altering the pH. SAL, therefore, has the potential to prevent the entry of SARS-CoV-2 into the cytosol and prevent membrane fusion (a pH-dependent process) [18] . It was reported that SAL has antiviral propensity by preventing the migration of nuclear protein (NP) to form a viral ribonuclear complex (VNP). This fails to acidify the endosomal-lysosomal compartments due to cytoplasmic accumulation of NP in the host cells [18, 19] . It was also reported that SAL could interact with S-protein, and influence ACE2 binding and prevent the release of viral RNA into the cytoplasm [20] . Besides, a recent drug screen identified SAL as a potential antiviral agent against SARS-CoV-2 (IC 50 =0.24µM) [19] . However, the clinical efficacy of SAL against SARS-CoV-2 needs to be evaluated. Pulmonary delivery is an attractive strategy for localized delivery of therapeutics to infection sites. Besides, inhaled nanoparticles overcomes the limitations of poor bioavailability and drug absorption. NLCs are biocompatible nanocarriers with good tolerability for pulmonary delivery. Due to their size in nanometers, NLCs can be easily aerosolized into droplets with suitable aerodynamical properties. This enables deep lung deposition of an active compound. Furthermore, NLCs adhere to the mucosal surface of the lung for a more extended period compared to larger particles due to the small size. Particle adhesion, accumulation, and retention in the lung as well as prolonged-release due to NLCs results in enhanced and sustained therapeutic effects. NLCs have advantage of better patient compliance [21] [22] [23] [24] [25] . All these advantages of inhaled NLCs play an essential role in the treatment of respiratory infections like COVID-19. There are several investigational drugs and drugs under preclinical trials for prevention/curative purposes of COVID-19, but still, there is no current approved drug. SAL has the ability to disruption concentration across the cell membrane and prevents virus entry into the host cells by selective targeting of SAL. Encapsulation of SAL in NLC for pulmonary delivery is an attractive approach for effective repurposing of SAL as an antiviral agent by improving its absorption at the infection site. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status Current Topics in Microbiology and Immunology/Ergebnisse der Mikrobiologie und Immunitätsforschung MERS, SARS and other coronaviruses as causes of pneumonia COVID-19: social distancing, ACE 2 receptors, protease inhibitors and beyond? Pathological findings of COVID-19 associated with acute respiratory distress syndrome Old drug, new tricks: realising the potential of repurposing Drug repurposing: progress, challenges and recommendations Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study Baricitinib for COVID-19: a suitable treatment? Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Experimental treatment with favipiravir for COVID-19: an open-label control study Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study A trial of lopinavirritonavir in adults hospitalized with severe Covid-19 Arguments in favour of remdesivir for treating SARS-CoV-2 infections Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and viral matrix protein 2 function Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19 Potential antivirals and antiviral strategies against SARS coronavirus infections Optimization of artemether-loaded NLC for intranasal delivery using central composite design Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art Nanostructured lipid carriers: promising drug delivery systems for future clinics Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA